Literature DB >> 19657977

Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment in adults and children in a tertiary referral center.

Carsten Heinz1, Jorg M Koch, Beatrix Zurek-Imhoff, Arnd Heiligenhaus.   

Abstract

PURPOSE: The aim of this study is to compare treatment strategies, the success of topical and systemic therapy, and the need for glaucoma surgery in children and adults with secondary uveitic glaucoma.
METHODS: Retrospective observational case series with 1997 consecutive new uveitis patients.
RESULTS: Overall, 176 patients (8.8%) suffered from secondary glaucoma (n = 126) or ocular hypertension (n = 50). All patients received topical therapy, and 107 (62%) patients also received systemic glaucoma therapy. Topical therapy was successful (IOP <or= 21 mmHg) in 24% of adults and 26% of children. Surgery was required in 59% of children and in 35% of adults (p =.02). The number of surgical interventions differed per patient with 2.6 procedures in children compared to 1.6 procedures in adults (p <.001).
CONCLUSIONS: Only a limited number of patients with secondary uveitic glaucoma can be sufficiently controlled with topical and systemic antiglaucomatous therapy alone. There is a significantly higher need for glaucoma operations in children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657977     DOI: 10.1080/09273940902913035

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  18 in total

Review 1.  [Uveitis in juvenile idiopathic arthritis].

Authors:  C Heinz; A Heiligenhaus; J Kümmerle-Deschner; I Foeldvari
Journal:  Z Rheumatol       Date:  2010-07       Impact factor: 1.372

2.  Long-term results of ab externo trabeculotomy for glaucoma secondary to chronic uveitis.

Authors:  Bogomil Voykov; Spyridon Dimopoulos; Martin Alexander Leitritz; Deshka Doycheva; Antony William
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-31       Impact factor: 3.117

Review 3.  Uveitis in juvenile idiopathic arthritis.

Authors:  Arnd Heiligenhaus; Kirsten Minden; Dirk Föll; Uwe Pleyer
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

4.  Canaloplasty in patients with uveitic glaucoma: a pilot study.

Authors:  Claudia Lommatzsch; Carsten Heinz; Arnd Heiligenhaus; Joerg Michael Koch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-07       Impact factor: 3.117

5.  Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.

Authors:  Sentaro Kusuhara; Atsuko Katsuyama; Wataru Matsumiya; Makoto Nakamura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-21       Impact factor: 3.117

6.  Clinical manifestation of Fuchs uveitis syndrome in childhood.

Authors:  Christoph Tappeiner; Jens Dreesbach; Martin Roesel; Carsten Heinz; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-19       Impact factor: 3.117

7.  Comparison of visual field defect progression in secondary Glaucoma due to anterior uveitis caused by three types of herpes viruses.

Authors:  Shintaro Shirahama; Toshikatsu Kaburaki; Sachiko Takada; Hisae Nakahara; Rie Tanaka; Keiko Komae; Yujiro Fujino; Hidetoshi Kawashima; Makoto Aihara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-12       Impact factor: 3.117

8.  [Trabeculectomy in uveitis associated with juvenile idiopathic arthritis: long-term results in pediatric secondary glaucoma].

Authors:  K Wiese; A Heiligenhaus; C Heinz
Journal:  Ophthalmologe       Date:  2014-04       Impact factor: 1.059

9.  Influence of optic disc leakage on objective optic nerve head assessment in patients with uveitis.

Authors:  Carsten Heinz; Katy Kogelboom; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-18       Impact factor: 3.117

Review 10.  Glucocorticoid therapy and ocular hypertension.

Authors:  Adnan Dibas; Thomas Yorio
Journal:  Eur J Pharmacol       Date:  2016-07-05       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.